Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study

Blood (2024) 144 (Supplement 1): 72.

https://doi.org/10.1182/blood-2024-199813

Published: 2024

Journal Articles

Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)

Blood (2024) 144 (Supplement 1): 748.

https://doi.org/10.1182/blood-2024-198021

Published: 2024

Journal Articles

Molecular Profiling and Disease Tracking of Post-Transplant Lymphoproliferative Diseases Using Cell-Free DNA

Nick Veltmaat, Yujie Zhong, Filipe Montes De Jesus, Johanna Bult, Pim Mutsaers, Wendy B.C. Stevens, Rogier Mous, Marjolein W.M. van der Poel, Martine E.D. Chamuleau, Walter Noordzij, Erik A.M. Verschuuren, Joost L. Kluiver, Arjan Diepstra, Wouter Plattel, Anke van den Berg, Marcel Nijland

Blood (2024) 144 (Supplement 1): 6234.

https://doi.org/10.1182/blood-2024-210000

Published: 2024

Journal Articles

Immunosuppressed Tumor Microenvironment in MYC -Rearranged High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas, Not Otherwise Specified

Blood (2024) 144 (Supplement 1): 4380.

https://doi.org/10.1182/blood-2024-205968

Published: 2024

Journal Articles

Comprehensive Analysis of Diagnosis, Treatment and Outcome in a Retrospective Cohort of HES Patients in the South-West of the Netherlands between 2000-2020

Yvonne Veltman, Anton Langerak, Berna Beverloo, Roel Fiets, Henk-Jan Boiten, Pim Mutsaers

Blood (2024) 144 (Supplement 1): 3906.

https://doi.org/10.1182/blood-2024-204613

Published: 2024

Journal Articles

ERG Is a New Predisposition Gene for Bone Marrow Failure and Hematological Malignancy

Blood (2023) 142 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2023-191986

Published: 2023

Journal Articles

DA-EPOCH-R for High Grade B-Cell Lymphoma Patients with MYC and BCL2 and/or BCL6 Rearrangements: Clinical Results of the Induction Phase of the HOVON-152 Trial

Blood (2023) 142 (Supplement 1): 3090.

https://doi.org/10.1182/blood-2023-181707

Published: 2023

Journal Articles

Results from the Cohort-Expansion Stage of a Phase I Trial of Tinostamustine Monotherapy in Advanced Hodgkin Lymphoma (HL), Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM) (NCT02576496)

Anna Maria Sureda Balari, Herve Ghesquieres, Franck Morschhauser, Pim Mutsaers, Enrique M Ocio, Tomas Janik, Nick Manamley, Kasia Hilgier, Pier Luigi Zinzani

Blood (2023) 142 (Supplement 1): 1706.

https://doi.org/10.1182/blood-2023-181822

Published: 2023

Journal Articles

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Jeremy S. Abramson, Scott R. Solomon, Jon Arnason, Patrick B. Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew Lunning, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Ken Ogasawara, Manali Kamdar

Blood (2023) 141 (14): 1675–1684.

https://doi.org/10.1182/blood.2022018730

Published: 2023

Includes: Supplemental data

Journal Articles

Plasma Extracellular Vesicle-Associated microRNAs for Early Response Prediction in Patients with High-Grade B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 3523–3524.

https://doi.org/10.1182/blood-2022-165494

Published: 2022

Journal Articles

Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 Transform Study

Jeremy S. Abramson, Scott R. Solomon, Jon E. Arnason, Patrick B. Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew A. Lunning, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Manali Kamdar

Blood (2022) 140 (Supplement 1): 1581–1583.

https://doi.org/10.1182/blood-2022-159702

Published: 2022

Journal Articles

Genomic Landscaping of Post-Transplant Lymphoproliferative Disorders Using Circulating Tumor DNA

Nick Veltmaat, Geok Wee Tan, Johanna A.A. Bult, Yujie Zhong, Wouter J. Plattel, Rogier Mous, Pim Mutsaers, Wendy B.C. Stevens, Joost S.P. Vermaat, Martine E.D. Chamuleau, Arjan Diepstra, Anke Van Den Berg, Filipe Montes De Jesus, Marcel Nijland

Blood (2022) 140 (Supplement 1): 9274–9276.

https://doi.org/10.1182/blood-2022-171213

Published: 2022

Journal Articles

Transcriptomics in Multiple Myeloma Demonstrates an Association between Survival and Expression of T Cell Co-Signaling Ligands in Bone Marrow Derived Myeloma Plasma Cells

Pim Mutsaers, MD, Rowan Kuiper, MSc, Dora Hammerl, Msc, Mark van Duin, PhD, Bronno Van Der Holt, PhD, Sonja Zweegman, MDPhD, Walter M Gregory, Jan J Cornelissen, MD PhD, Annemiek Broyl, MD PhD, Reno Debets, PhD, Pieter Sonneveld, MDPhD

Blood (2018) 132 (Supplement 1): 241.

https://doi.org/10.1182/blood-2018-99-118488

Published: 2018

Journal Articles

Familial AML With Germline CEBPA Mutations: Extended Clinical Outcomes and Analysis Of Secondary Mutations Using Whole Exome Sequencing

Kiran Tawana, MD, Aline Renneville, Jun Wang, PhD, Panayiotis Georgiades, Xavier Thomas, MD, Valerie Mialou, MD, Aleksander Savic, MD, Frederik W Van Delft, MD PhD, Jennifer G. Treleaven, MD, Sameena Iqbal, Norio Asou, MD, PhD, Naokuni Uike, MD, Konstanze Döhner, MD, Lars Bullinger, MD, PhD, Matthias Stelljes, MD, Csaba Bödör, PhD, James D. Cavenagh, MD, Doris Steinemann, PhD, Tim Ripperger, MD, Brigitte Schlegelberger, MD, PhD, Peter Vandenberghe, MD, PhD, Anne Uyttebroeck, MD, Josep F. Nomdedeu, MD, Henrik Hjorth-Hansen, MD, PhD, Rosemary E Gale, PhD, Cynthia L. Toze, MD, FRCP(C), Michael J. Barnett, BMBS, FRCPC, FRCP, FRCPath, Marianna Zombori, MD, Krisztian Kallay, MD, Jiri Pavlu, MD, Pim Mutsaers, MD, Fred H Menko, MD, Angela Thomas, PhD, FRCPath, FRCP, MB, BS, Christine Wright, MD, Jessica Okosun, MD, Chey Loveday, PhD, Pierre Fenaux, MD, PhD, Hamish Scott, PhD, Claude Preudhomme, Claude Chelala, PhD, Alison Male, MD, Carolyn J. Owen, MD, FRCPC, Matthew Smith, MD, PhD, Jude Fitzgibbon, PhD

Blood (2013) 122 (21): 740.

https://doi.org/10.1182/blood.V122.21.740.740

Published: 2013

NARROW

Circulating Tumor DNA (ctDNA) As an Early Outcome Predictor in Patients (pts) with Second-Line (2L) Large B-Cell Lymphoma (LBCL) after Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) Treatment (tx) from the Phase 3, Randomized Transform Study

Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)

Molecular Profiling and Disease Tracking of Post-Transplant Lymphoproliferative Diseases Using Cell-Free DNA

Immunosuppressed Tumor Microenvironment in MYC -Rearranged High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas, Not Otherwise Specified

Comprehensive Analysis of Diagnosis, Treatment and Outcome in a Retrospective Cohort of HES Patients in the South-West of the Netherlands between 2000-2020

ERG Is a New Predisposition Gene for Bone Marrow Failure and Hematological Malignancy

DA-EPOCH-R for High Grade B-Cell Lymphoma Patients with MYC and BCL2 and/or BCL6 Rearrangements: Clinical Results of the Induction Phase of the HOVON-152 Trial

Results from the Cohort-Expansion Stage of a Phase I Trial of Tinostamustine Monotherapy in Advanced Hodgkin Lymphoma (HL), Non-Hodgkin Lymphoma (NHL) and Multiple Myeloma (MM) (NCT02576496)

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Plasma Extracellular Vesicle-Associated microRNAs for Early Response Prediction in Patients with High-Grade B-Cell Lymphoma

Genomic Landscaping of Post-Transplant Lymphoproliferative Disorders Using Circulating Tumor DNA

Transcriptomics in Multiple Myeloma Demonstrates an Association between Survival and Expression of T Cell Co-Signaling Ligands in Bone Marrow Derived Myeloma Plasma Cells

Familial AML With Germline CEBPA Mutations: Extended Clinical Outcomes and Analysis Of Secondary Mutations Using Whole Exome Sequencing

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only